Navigation Links
Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkin's Lymphoma Presented at ASH Meeting
Date:12/13/2011

NEW YORK, Dec. 13, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) (the "Company") today reported that encouraging clinical data from a Phase 2 clinical study in patients with refractory/relapsed Hodgkin's Lymphoma was presented yesterday during the Annual Meeting of the American Society of Hematology, which is currently being held in San Diego, California. In a poster presentation by Anna Guidetti, MD, Fondazione IRCCS Instituto Nazionale Tumori, Milan, Italy, preliminary response data showed that perifosine combined with sorafenib significantly increased median progression free survival (PFS) in refractory/relapsed Hodgkin's Lymphoma patients with high phosphorylation levels of Erk and Akt as compared to patients with low baseline phosphorylation levels of Erk and Akt. 

The Phase 2 Study

In abstract # 3705, entitled "Phosphorylation Levels of Extracellular-Signal Regulated Kinase (Erk) and Akt in Circulating Lymphocytes Predict Response to Targeted Therapy with Perifosine and Sorafenib in Refractory/Relapsed Hodgkin Lymphoma Patients,"  phosphorylation levels of Erk (pErk) and Akt (pAkt) were evaluated in circulating lymphocytes from patients enrolled in two consecutive Phase 2 trials evaluating the activity and safety of sorafenib as a single agent or in combination with perifosine in relapsed/refractory Hodgkin Lymphoma patients.

Four patients were treated with sorafenib alone at a dose level of 400mg BID and twenty-one patients received a 4-week treatment with perifosine alone at a dose level of 50mg BID followed by a perifosine/sorafenib combination therapy with 50mg BID and 400mg BID, respectively. Circulated lymphocytes were evaluated for their phosphorylation levels of Erk and
Akt in order to assess predictive value of the phosphokinase levels for therapy responses.

R
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
5. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
8. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
9. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
10. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... July 11, 2014  Veran Medical Technologies, ... today the positive, cost-effective final results for ... procedure. The SPiNPerc endobronchial percutaneous biopsy study ... approach to biopsy when a traditional bronchoscopic ... physicians experience positive financial outcomes when more ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
(Date:7/12/2014)... July 12, 2014 As reported in ... of Standards and Technology), the June 25th, 2014 Supreme Court ... discovery world. It was also met with both ... on whether it was seen from an individual privacy perspective, ... is fact, there is now precedent which will require law ...
(Date:7/12/2014)... July 12, 2014 A recent article released ... a trio of suggestions for those seeking cosmetic surgical ... are rapidly approaching and the heat begins to enliven the ... their summer clothing, realizing that they didn’t work out as ... This can cause a sudden surge of people eager to ...
(Date:7/12/2014)... Seattle, Wa (PRWEB) July 12, 2014 ... by Doctors Sen and Samantha Pearson, a couple boasting ... chose to launch Restore My Vision Today as a ... that many ophthalmologists have become in their respective ... makes readers privy to a “secret” trove of pertinent ...
(Date:7/12/2014)... 2014 The largest pure occupational medicine ... to announce that it will be opening its fifth ... will join four Atlanta-based Nova Medical Centers’ locations. The ... Deans Bridge Road, and will be open from 8:30 ... “With Nova’s treatment philosophy of rapid return-to-work and decreased ...
(Date:7/11/2014)... DressyQuinceanera.com, a well-known wedding dress manufacturer and retailer, has ... online category. Furthermore, the firm has announced that all ... to 62% off. , The brand new Quinceanera Dama ... quality and style. All items in the new collection ... the company’s other items: lace evening dresses, short bridesmaid ...
Breaking Medicine News(10 mins):Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2
... (January 25, 2008) Research in the January issue ... (JACS) shows that many patients with minimal injuries ... and II trauma centers, despite the ability of the ... that overuse of trauma centers threatens to limit the ...
... Inc. (NYSE: WTW ) announced today that ... Sardini, Chief Financial,Officer, will present at the Credit ... The presentation will be held on Tuesday, ... a.m. local time) and will be accessible via ...
... to encourage Americans to ... 25 , Who: "The Biggest Loser" Season Four winner Bill Germanakos ... with MSN Health & Fitness and ... discuss "The Biggest Loser" Million Pound Match-Up sweepstakes, at ...
... Doctors Care is,pleased to announce the opening of its ... Hoffmeyer Road, Florence. The new center opened,January 23, 2008. ... scheduled to,open soon., Dr. Thomas Gibbons, the Midlands ... "Doctors Care is excited to provide convenient,urgent care, family ...
... 300-bed facility in Tempe, Arizona, raises MDS capacity in the ... Phoenix-area to 420 ... MDS Pharma,Services (http://www.mdsps.com ), a leading provider of innovative drug ... a new 300-bed Phase I facility in nearby Tempe, Arizona. The ...
... Md., Jan. 25 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... commercializing novel anti-infective products, today,announced that it has ... the private placement of 8,750,000 shares of,its common ... includes,five-year warrants to purchase 3,500,000 shares of common ...
Cached Medicine News:Health News:Excessive overtriage in US trauma centers overwhelming system resources, delaying patient care 2Health News:Weight Watchers to Present at Credit Suisse 10th Annual Global Services Conference 2Health News:Bill Germanakos and Hollie Self Bring 'The Biggest Loser' Million-Pound Tour, Presented by MSN, to Arizona Mills Mall 2Health News:UCI Medical Affiliates Inc. Opens New Doctors Care Center in Florence 2Health News:MDS Pharma Services Opens Largest Phase I Clinic on U.S. West Coast 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 3Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: